>The "partner" will provide the funding of the operations for the forseeable future obviating the need for money from present partners or for any drastic reduction in their pipeline.<
This sounds like a financial partnership rather than a development and commercialization partnership. Many biotechs companies do have such an arrangement with a financial backer, but this is contrary to what GTC has publicly stated vis-à-vis the kind of partnership under consideration.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”